SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Rosinbomb (ROSN) trades at a trailing P/E of 200.0. Trailing earnings yield is 0.50%.
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 200.0); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.50%).
- Trailing Earnings Yield 0.50% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
Overall SharesGrow Score: 22/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ROSN
Valuation Multiples
P/E (TTM)200.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings Yield0.50%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.00 |
$0.00 |
$-19.83K |
- |
| 2017 |
$0.00 |
$18.83K |
$1.78K |
9.4% |
| 2018 |
$0.00 |
$524.58K |
$-91.25K |
-17.4% |
| 2019 |
$0.00 |
$528.91K |
$-1.12M |
-211.8% |
| 2020 |
$0.00 |
$693.24K |
$-490.93K |
-70.8% |
| 2021 |
$-0.02 |
$1.08M |
$-5.92M |
-548.8% |
| 2022 |
$0.00 |
$269.77K |
$-298.45K |
-110.6% |
| 2023 |
$0.00 |
$98.2K |
$-80.48K |
-82% |
| 2024 |
$0.00 |
$0.00 |
$-71.98K |
- |
| 2025 |
$0.00 |
$0.00 |
$-25.1K |
- |
